Sarah Rutherford, MD, Weill Cornell Medical College

Articles by Sarah Rutherford, MD, Weill Cornell Medical College

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in CLL

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

Latest Updated Articles

$ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas$
ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas
January 22nd 2021
ASH 2020 Updates in CLL
January 22nd 2021
ASH 2020 Updates in Non-CLL B-Cell Lymphomas
January 22nd 2021

Trending on OncLive

Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL

Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer

FSHR-Directed CAR T-Cell Therapy Yields Instance of Stable Disease in Recurrent Ovarian Cancer

‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center

Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC